Cargando…

Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA

BACKGROUND: To determine the prevalence of detectable serum hepatitis B virus (HBV) DNA in patients who are hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody (HBcAb)-positive. The correlation between HBV DNA viral load and serological markers, as well as liver and coagulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Jingyao, Wu, Weimin, Wu, Jiali, Chen, Zhiyang, Wu, Ziwei, Tang, Yamei, Hu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825549/
https://www.ncbi.nlm.nih.gov/pubmed/35242870
http://dx.doi.org/10.21037/atm-21-6272
_version_ 1784647238832619520
author Cai, Jingyao
Wu, Weimin
Wu, Jiali
Chen, Zhiyang
Wu, Ziwei
Tang, Yamei
Hu, Min
author_facet Cai, Jingyao
Wu, Weimin
Wu, Jiali
Chen, Zhiyang
Wu, Ziwei
Tang, Yamei
Hu, Min
author_sort Cai, Jingyao
collection PubMed
description BACKGROUND: To determine the prevalence of detectable serum hepatitis B virus (HBV) DNA in patients who are hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody (HBcAb)-positive. The correlation between HBV DNA viral load and serological markers, as well as liver and coagulation function indicators were investigated. Furthermore, the effects of immunosuppressive therapy on DNA replication were assessed. METHODS: A total of 2,013 HBsAg-negative/HBcAb-positive patients admitted to our hospital between January and December 2019 were enrolled in this study. Patient clinical characteristics including serological markers, HBV DNA viral load, liver function and coagulation function indicators, and immune function status were analyzed. RESULTS: In the Hunan province in China, the prevalence of detectable HBV DNA was 5.4% in HBsAg-negative/HBcAb-positive patients. However, the prevalence of detectable HBV DNA in HBsAg-negative/HBcAb-positive patients may vary because of different HBV serological markers. In patients with detectable serum HBV DNA, the log10 HBV DNA value was positively correlated with alanine transaminase (ALT) and aspartate transaminase (AST) levels, and negatively correlated with antithrombin III (AT III) concentrations. Moreover, in patients receiving immunosuppressive therapy, ALT and AST levels were higher than those of patients who did not receive immunosuppressive therapy. The ALT and AST levels in hepatitis B e antibody (HBeAb)-positive patients were significantly higher than that observed in HBeAb-negative patients. CONCLUSIONS: For HBsAg-negative/HBcAb-positive patients, clinicians should pay attention to the patient's immune function status. In situations where HBV DNA cannot be detected, changes in serum ALT, AST, and AT III concentrations can be used to speculate on viral replication status to reduce the risk of HBV infection and transmission.
format Online
Article
Text
id pubmed-8825549
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-88255492022-03-02 Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA Cai, Jingyao Wu, Weimin Wu, Jiali Chen, Zhiyang Wu, Ziwei Tang, Yamei Hu, Min Ann Transl Med Original Article BACKGROUND: To determine the prevalence of detectable serum hepatitis B virus (HBV) DNA in patients who are hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody (HBcAb)-positive. The correlation between HBV DNA viral load and serological markers, as well as liver and coagulation function indicators were investigated. Furthermore, the effects of immunosuppressive therapy on DNA replication were assessed. METHODS: A total of 2,013 HBsAg-negative/HBcAb-positive patients admitted to our hospital between January and December 2019 were enrolled in this study. Patient clinical characteristics including serological markers, HBV DNA viral load, liver function and coagulation function indicators, and immune function status were analyzed. RESULTS: In the Hunan province in China, the prevalence of detectable HBV DNA was 5.4% in HBsAg-negative/HBcAb-positive patients. However, the prevalence of detectable HBV DNA in HBsAg-negative/HBcAb-positive patients may vary because of different HBV serological markers. In patients with detectable serum HBV DNA, the log10 HBV DNA value was positively correlated with alanine transaminase (ALT) and aspartate transaminase (AST) levels, and negatively correlated with antithrombin III (AT III) concentrations. Moreover, in patients receiving immunosuppressive therapy, ALT and AST levels were higher than those of patients who did not receive immunosuppressive therapy. The ALT and AST levels in hepatitis B e antibody (HBeAb)-positive patients were significantly higher than that observed in HBeAb-negative patients. CONCLUSIONS: For HBsAg-negative/HBcAb-positive patients, clinicians should pay attention to the patient's immune function status. In situations where HBV DNA cannot be detected, changes in serum ALT, AST, and AT III concentrations can be used to speculate on viral replication status to reduce the risk of HBV infection and transmission. AME Publishing Company 2022-01 /pmc/articles/PMC8825549/ /pubmed/35242870 http://dx.doi.org/10.21037/atm-21-6272 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Cai, Jingyao
Wu, Weimin
Wu, Jiali
Chen, Zhiyang
Wu, Ziwei
Tang, Yamei
Hu, Min
Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA
title Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA
title_full Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA
title_fullStr Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA
title_full_unstemmed Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA
title_short Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA
title_sort prevalence and clinical characteristics of hepatitis b surface antigen-negative/hepatitis b core antibody-positive patients with detectable serum hepatitis b virus dna
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825549/
https://www.ncbi.nlm.nih.gov/pubmed/35242870
http://dx.doi.org/10.21037/atm-21-6272
work_keys_str_mv AT caijingyao prevalenceandclinicalcharacteristicsofhepatitisbsurfaceantigennegativehepatitisbcoreantibodypositivepatientswithdetectableserumhepatitisbvirusdna
AT wuweimin prevalenceandclinicalcharacteristicsofhepatitisbsurfaceantigennegativehepatitisbcoreantibodypositivepatientswithdetectableserumhepatitisbvirusdna
AT wujiali prevalenceandclinicalcharacteristicsofhepatitisbsurfaceantigennegativehepatitisbcoreantibodypositivepatientswithdetectableserumhepatitisbvirusdna
AT chenzhiyang prevalenceandclinicalcharacteristicsofhepatitisbsurfaceantigennegativehepatitisbcoreantibodypositivepatientswithdetectableserumhepatitisbvirusdna
AT wuziwei prevalenceandclinicalcharacteristicsofhepatitisbsurfaceantigennegativehepatitisbcoreantibodypositivepatientswithdetectableserumhepatitisbvirusdna
AT tangyamei prevalenceandclinicalcharacteristicsofhepatitisbsurfaceantigennegativehepatitisbcoreantibodypositivepatientswithdetectableserumhepatitisbvirusdna
AT humin prevalenceandclinicalcharacteristicsofhepatitisbsurfaceantigennegativehepatitisbcoreantibodypositivepatientswithdetectableserumhepatitisbvirusdna